Dr David Barry, Former Director Global R&D

Dr Barry qualified as a doctor and worked on viral vaccines in the public sector before moving to BW in 1977. In 1994 he became the first Global Research and Development Director, the aim being to unite the research operation which was then divided between UK and USA. At the time of the interview he was Chairman and CEO of Triangle Pharmaceuticals.

Topics discussed include:

* biography

* working atmosphere and changes within the company in the 1980s

* George Hitchings, Pedro Cuatrecasas and Gertude Elion

* relationship between US and UK research functions, and the restructure into single unit in 1994 under Barry

* Mckinsey report and the effects on the research department

* Bill Sullivan

* Beckenham site - structure and focus, refers to some staff - John Vane, Trevor Jones and Jimmy Black

* acyclovir

* description of a mid 1990s special shareholder meeting

* Glaxo takeover

* comments on how being a non-public body affected the way BW was run

* AZT [marketed as Retrovir, for use against HIV/Aids] : development, submission to FDA, pricing

* Wellbutrin

No tape is available for this interview

1 file Tape 12: this was not transferred to the Wellocme Library

Copyright was assigned to the Wellcome Trust for all material created or commissioned by the Wellcome Foundation, its successors and associated companies. The copyright in third party material (ie material not created by WF such as letters and publications from external sources, magazine articles, newspaper cuttings etc) is assumed to remain with the creator or his/her heirs. Where third party material exists, this has been noted at item level.